home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Diamond Collection
/
The Diamond Collection (Software Vault)(Digital Impact).ISO
/
cdr16
/
med9505a.zip
/
M9550213.TXT
< prev
next >
Wrap
Text File
|
1995-03-04
|
2KB
|
38 lines
Document 0213
DOCN M9550213
TI Antiretroviral therapy for children.
DT 9505
AU Krasinski K; Department of Pediatrics, New York University Medical
Center, New; York.
SO Acta Paediatr Suppl. 1994 Aug;400:63-9. Unique Identifier : AIDSLINE
MED/95135023
AB Advances in the development of antiviral drugs have been rapid and
dramatic. Since the recognition of HIV-1 as the cause of AIDS in 1984,
and improved understanding of retroviral replication and pathogenesis,
three antiviral drugs, Zidovudine, Didanosine, and Zalcitabine, have
been developed to the point of routine use in humans. There is
substantial experience with the former two in children. Despite being
unable to cure HIV-1 infection, the benefits of antiretroviral therapy,
including extended survival and reductions in opportunistic infections
in adults, and improved weight gain and well-being in children, are
strong arguments for routine treatment of symptomatic disease. Because
these agents may also interfere with human cellular processes and have
toxicities including anemia, neutropenia, pancreatitis, and neuropathy,
their routine use for the treatment of asymptomatic children requires
further controlled study. There are multiple candidate agents being
developed for entry into clinical trials. An additional potentially
effective strategy is the use of combinations of drugs at the same time
or in sequence to maximize the viral targets being attacked, while
minimizing toxicity, and to prevent the emergence of a drug-resistant
virus.
DE Acquired Immunodeficiency Syndrome/*DRUG THERAPY/IMMUNOLOGY/ VIROLOGY
Adult Child Clinical Trials Controlled Clinical Trials
Didanosine/*THERAPEUTIC USE Drug Resistance, Microbial DNA,
Viral/ANALYSIS Human HIV-1/*DRUG EFFECTS/GENETICS/PHYSIOLOGY
Immunity, Cellular Virus Replication Zalcitabine/*THERAPEUTIC USE
Zidovudine/*THERAPEUTIC USE JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).